Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months. Issue 6 (29th June 2021)

• Record Type: Journal Article
• Authors: Robertson, Louise J; Moore, Julie S; Blighe, Kevin; Ng, Kok Yew; Quinn, Nigel; Jennings, Fergal; Warnock, Gary; Sharpe, Peter; Clarke, Mark; Maguire, Kathryn; Rainey, Sharon; Price, Ruth K; Burns, William P; Kowalczyk, Amanda M; Awuah, Agnes; McNamee, Sara E; Wallace, Gayle E; Hunter, David; Sager, Steve; Chao Shern, Connie; Nesbit, M Andrew; McLaughlin, James A D; Moore, Tara
• Is Part Of: BMJ open. Volume 11:Issue 6(2021)
• Publication Date: 2021-06-29
• Subjects: COVID-19 -- molecular diagnostics -- diagnostic microbiology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2020-048142
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objective: To evaluate the dynamics and longevity of the humoral immune response to SARS-CoV-2 infection and assess the performance of professional use of the UK-RTC AbC-19 Rapid Test lateral flow immunoassay (LFIA) for the target condition of SARS-CoV-2 spike protein IgG antibodies. Design: Nationwide serological study. Setting: Northern Ireland, UK, May 2020–February 2021. Participants: Plasma samples were collected from a diverse cohort of individuals from the general public (n=279), Northern Ireland healthcare workers (n=195), pre-pandemic blood donations and research studies (n=223) and through a convalescent plasma programme (n=183). Plasma donors (n=101) were followed with sequential samples over 11 months post-symptom onset. Main outcome measures: SARS-CoV-2 antibody levels in plasma samples using Roche Elecsys Anti-SARS-CoV-2 IgG/IgA/IgM, Abbott SARS-CoV-2 IgG and EuroImmun IgG SARS-CoV-2 ELISA immunoassays over time. UK-RTC AbC-19 LFIA sensitivity and specificity, estimated using a three-reference standard system to establish a characterised panel of 330 positive and 488 negative SARS-CoV-2 IgG samples. Results: We detected persistence of SARS-CoV-2 IgG antibodies for up to 10 months post-infection, across a minimum of two laboratory immunoassays. On the known positive cohort, the UK-RTC AbC-19 LFIA showed a sensitivity of 97.58% (95.28% to 98.95%) and on known negatives, showed specificity of 99.59% (98.53 % to 99.95%). Conclusions: Through comprehensive analysis of a cohort of pre-pandemic and pandemic individuals, we show detectable levels of IgG antibodies, lasting over 46 weeks when assessed by EuroImmun ELISA, providing insight to antibody levels at later time points post-infection. We show good laboratory validation performance metrics for the AbC-19 rapid test for SARS-CoV-2 spike protein IgG antibody detection in a laboratory-based setting.